Livforsakringsbolaget Skandia Omsesidigt Sells 100 Shares of Amgen Inc. (NASDAQ:AMGN)

Livforsakringsbolaget Skandia Omsesidigt trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 0.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 47,218 shares of the medical research company’s stock after selling 100 shares during the period. Amgen accounts for approximately 0.7% of Livforsakringsbolaget Skandia Omsesidigt’s investment portfolio, making the stock its 28th biggest position. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Amgen were worth $12,306,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Amgen by 1.2% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,594,828 shares of the medical research company’s stock worth $415,676,000 after purchasing an additional 19,053 shares during the period. Strategic Financial Concepts LLC acquired a new position in shares of Amgen during the fourth quarter worth $9,313,000. Consolidated Portfolio Review Corp acquired a new position in shares of Amgen during the fourth quarter worth $1,216,000. Telos Capital Management Inc. lifted its holdings in shares of Amgen by 3.2% during the fourth quarter. Telos Capital Management Inc. now owns 25,997 shares of the medical research company’s stock worth $6,776,000 after purchasing an additional 797 shares during the period. Finally, GHP Investment Advisors Inc. lifted its holdings in shares of Amgen by 6.3% during the fourth quarter. GHP Investment Advisors Inc. now owns 26,486 shares of the medical research company’s stock worth $6,903,000 after purchasing an additional 1,572 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Down 3.3 %

NASDAQ:AMGN opened at $297.78 on Friday. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The firm has a 50-day moving average of $271.69 and a 200-day moving average of $303.55. The company has a market cap of $160.07 billion, a PE ratio of 38.13, a PEG ratio of 2.87 and a beta of 0.56. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 13.00% and a return on equity of 168.35%. As a group, equities research analysts expect that Amgen Inc. will post 19.56 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.20%. Amgen’s payout ratio is 126.09%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on AMGN shares. StockNews.com lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Wolfe Research began coverage on shares of Amgen in a research note on Friday, November 15th. They set a “peer perform” rating for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $405.00 target price on shares of Amgen in a research note on Tuesday, October 22nd. Jefferies Financial Group reissued a “buy” rating and set a $380.00 target price on shares of Amgen in a research note on Tuesday, November 12th. Finally, Piper Sandler lowered their target price on shares of Amgen from $344.00 to $310.00 and set an “overweight” rating for the company in a research note on Thursday, January 2nd. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus price target of $314.83.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,589 shares of the business’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.69% of the stock is owned by corporate insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.